IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and ...

Cytokine networks demonstrate dual functionality. Cytokines are key regulators of immune homeostasis, but paradoxically, cytokines also function as pathogenic drivers in diseases such as systemic ...

Discover how targeted therapies are revolutionizing autoimmune disease treatment by offering greater precision.

Giant cell arteritis (GCA) is the most frequent primary systemic vasculitis in adults, involving medium-to-large-sized vessels. It ...

Obefazimod’s strong Phase 3 induction data positions Abivax as leading UC contender with novel mechanism and favorable safety ...

Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation: Palo Alto, California Saturday, July 19, 2025, 16:30 Hrs [IST] ...

Chimeric antigen receptor T cell therapy has reshaped expectations for treating hematological malignancies and is now reaching toward autoimmune ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key ...

Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between ...

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Current approaches in bioengineering are synthesized and methods for their implementation are suggested for the induction and modulation of trained immunity in the treatment of human diseases.